Benzinga
23 Dec 2025, 18:05 UTC · 38w ago
Verdict
Headline takes no side. We score BMRN +0.80 across four claims — strongly bullish.
+0.80strongly bullish
More positive than 83% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
BioMarin Pharmaceutical Inc. agreed to acquire Amicus Therapeutics for a total equity value of approximately $4.8 billion.
More positive than 92% of claims this week
The acquisition is expected to be accretive to Non-GAAP Diluted EPS within the first 12 months following the close.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
More positive than 76% of claims this week
BioMarin expects the acquired assets to each generate approximately $1 billion in peak sales in the 2030s.
So whatLong-term revenue growth projections provide a fundamental bullish case for the company's valuation.
More positive than 62% of claims this week
Truist Securities raised its price target for BioMarin from $80 to $100 following the deal announcement.
So whatAnalyst upgrades and price target increases often act as short-term positive signals for investors.
More positive than 50% of claims this week
Which stocks this story touches
More positive than 83% of ticker scores this week
The company is acquiring Amicus Therapeutics, receiving analyst price target upgrades, and showing bullish technical momentum.
More positive than 70% of ticker scores this week
The company is being acquired by BioMarin for a total equity value of approximately $4.8 billion.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Business Wire
1h ago
+7.9%
Price agrees with the score
$63.94 vs $59.28 close before publication (Dec 22) · not market-adjusted
BMRN chart →
